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Abstract
Introduction: Despite their high toxicity, antimonials and amphotericin B deoxycholate are commonly used for treating visceral 
leishmaniasis (VL). Few studies showing conflictive data about their efficacy and adverse events in pediatric population are available. 
This study aimed to evaluate efficacy and safety of amphotericin B deoxycholate vs. that of N-methylglucamine antimoniate in 
treating pediatric VL in Brazil. Methods: This was a randomized, open-label, 2-arm and controlled pilot clinical trial. Treatment 
naïve children and adolescents with VL without signs of severe illness were treated with N-methylglucamine antimoniate (20mg/
kg/day for 20 days) or amphotericin B deoxycholate (1mg/kg/day for 14 days). All patients were diagnosed with positive direct 
examination and/or positive PCR for Leishmania spp. performed in bone marrow samples. The primary efficacy end-point was 
VL cure determined after 180 days of completion of treatment. The analysis was performed using intention-to-treat (ITT) and per 
protocol (PP) analyses. Results: In total, 101 volunteers were assessed. Efficacy was similar for both groups. The antimonial (n=51) 
and amphotericin B groups (n=50) had a cure rate of 94.1% and 100%, and 94% and 97.9% according to ITT and PP analyses, 
respectively. All patients reported adverse events (AE). Serious AE incidence was similar in both groups. Five individuals were 
excluded from the study because of severe adverse events. Conclusions: N-methylglucamine antimoniate and amphotericin B 
deoxycholate have similar efficacy and adverse events rate in pediatric patients with VL.
Keywords: Visceral leishmaniasis. Children. Clinical trial. Brazil.
INTRODUCTION
Visceral leishmaniasis (VL) is a neglected infectious disease 
prevalent in children. In recent decades, its epidemiological 
features have changed in Brazil. In the past, VL was prevalent 
predominantly in rural environments; however, in recent 
years, it has been transmitted predominantly in urban and 
peri-urban areas1. Over the last decade, studies have increased 
the knowledge of diagnostic tools and efficacy of available 
leishmanicidal drugs. Nevertheless, clinical trials are scarce, 
especially among children2,3.
According to Brazilian Ministry of Health, 3,453 individuals 
were diagnosed with VL in 2014, of which 52% were children 
and teenagers aged <19 years. Although 58.6% of VL cases 
occurred in Northeastern states, the state with the highest 
prevalence was Tocantins (10.8/100,000 population, more than 
6 times the prevalence in Brazil in 2014, 1.7/100,000)4.
Clinical features of VL mainly depend on the parasite-host 
relationship. Immunocompetent patients can resist parasitic 
infection, while parasite development is possible in anergic 
patients, resulting in typical systemic manifestations of the 
disease5. Splenomegaly and fever are the most important and 
common VL manifestations. Spleen size was found to be 
proportional with disease duration6.
Drugs for VL have complex pharmacological properties. 
American VL needs parenteral administration of drugs 
with high toxicity levels7. Brazilian Ministry of Health 
suggested antimonials as first-line VL treatment and liposomal 
amphotericin B for patients at high mortality risk (infants, adults 
aged >50 years, immunosuppressed patients, patients with renal, 
hepatic or cardiac failure, etc.)8. Although drugs indicated for 
VL therapy in Brazil have been used for decades, few studies 
comparing their efficacy and safety in the pediatric population 
are available. Additionally, antimonial use in outpatient settings 
precludes detailed laboratory investigation of possible toxic 
effects and early identification of drug toxicity. Therefore, the 
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aim of this study was to estimate the efficacy and safety of 
amphotericin B deoxycholate (ABD) through a randomized and 
controlled clinical trial compared to meglumine antimoniate 
(MA) in children with VL treated in reference centers of 
Palmas (Tocantins’ State Capital) and Araguaína, the two most 
populated cities in the State of Tocantins, Brazil.
METHODS
Study design and participants
This was an open-label, randomized, and controlled trial 
with masking laboratory outcomes. It was performed in Dona 
Regina Hospital in Palmas and Tropical Diseases Hospital in 
Araguaína city. Since analyzed drugs are marketed in Brazil, the 
survey was registered as a Phase IV study; however, it presented 
methodological characteristics of a phase III pilot clinical trial. 
Eligible patients were children aged 6 months-12 years who 
met the inclusion criteria for VL diagnosis (presence of fever for 
at least two weeks associated with splenomegaly). The diagnosis 
of VL was confirmed by visualization of Leishmania spp. 
amastigotes in direct bone marrow microscopic examination or 
parasitic deoxyribonucleic acid (DNA) detection by polymerase 
chain reaction (PCR). Participation in this study was voluntary 
upon the signature of the informed consent form by the patients' 
parents or legal guardians. Exclusion criteria were the following: 
patients who underwent previous treatment with leishmanicidal 
drugs, clinically evident jaundice (total bilirubin > 2.5mg/dL), 
hemorrhages with coagulation disorders, generalized edema, 
signs of toxemia, severe malnutrition according to Gómez 
criteria9, presence of comorbidities or immunosuppressive 
conditions, and lack of informed consent. Finally, 101 patients 
were included and underwent the randomization process 
between January 2007 and July 2009 (Figure 1).
Ethical consideration
This study attempted to continuously balance both individual 
and collective risks and benefits of the evaluated drugs used, 
always seeking maximum benefits and minimum risk or harm, 
and to avoid any damage, such as drug toxicity. The study was 
conducted strictly in accordance to the 196/96 Resolution of 
Brazilian Health Council. The parents or legal guardians of eligible 
patients received detailed explanation of the study protocol and 
provided written consent. The study protocol was approved by the 
Ethics Research Committee of the Federal University of Tocantins 
and complied with the tenets of the Declaration of Helisnki. 
All interventions were performed at no charge to the patients. 
Interventions
Eligible patients underwent complete medical history and 
laboratory assessments. Samples were collected for complete 
blood count, human immunodeficiency virus (HIV) serology, 
prothrombin activity, bilirubin, aminotransferases, albumin, and 
globulin levels, and urinalysis. Blood and bone marrow samples 
were collected for VL diagnosis. Indirect immunofluorescence 
test (IFAT), rapid immunoassay (Kala-azar Detect®; InBios 
International, Seattle, WA), and standard polymerase chain 
reaction (PCR) for Leishmania spp. detection in the blood were 
performed. Bone marrow samples were obtained for direct 
microscopic examination to detect amastigotes of Leishmania 
spp., culture of Leishmania spp. in a biphasic medium, and PCR 
to amplify the conserved target region of 120bp of Leishmania 
kinetoplast deoxyribonucleic acid (kDNA)10. All patients 
underwent clinical and laboratory evaluation on days 0, 3, 7, 
14, 21, 28, 60, 90, 120, 150, and 180.
Based on the randomization list, patients were administered 
either antimonial (antimonial group) or amphotericin B 
(ABD group). The treatment was administered using MA 
(Glucantime®, Aventis Pharma Ltda., Brazil) 20mg/kg/day 
IV for 20 days (antimonial group) and ABD 1mg/kg/day IV 
administered diluted in 5% glucose (concentration of 0.1mg/
ml) infused for 6h for 14 days (ABD group).
All 4,500 ampoules of MA belonged to a single batch 
(603090, expiration date: Jun/2011). The 2,100 vials of ABD 
(Laboratório Cristália, Brazil) also belonged to the same batch 
(06085604, expiration date: Aug/2009). All drugs were provided 
by the Brazilian Ministry of Health.
Objectives
The primary objective was to evaluate the efficacy and safety 
of ABD compared to MA in children with visceral leishmaniasis. 
Secondary objective was to compare the time until clinical and 
hematological recovery between the groups.
Outcomes
Primary outcomes were clinical cure evaluated at day 180 
of follow-up (D180) and prevalence of serious adverse events 
among patients, which required medication discontinuation and 
were excluded from the study.
Cure was defined as follows: complete remission of clinical 
signs and symptoms up to three months after treatment completion, 
normalization of hematological changes, and no recurrence of 
VL until the sixth month of follow-up. Recurrence was defined 
as the resurgence or reappearance of VL signs or symptoms after 
an improvement period or after clinical cure during the 6-month 
follow-up. Therapeutic failure was defined as any outcome different 
from cure. We included the interruption due to severe toxicity or 
drug intolerance, in the definition of therapeutic failure. In these 
cases, MA or ABD were replaced by liposomal amphotericin B.
Secondary outcomes included the following: time elapsed 
until fever resolution, time to 50% reduction of splenomegaly, 
time elapsed until normalization of RBC indices (hemoglobin 
and hematocrit), lethality rate, time elapsed until normalization 
of other laboratory parameters, and the overall rate of adverse 
events associated with drug use. The primarily analyzed adverse 
events were heart failure, kidney failure, liver failure, pancreatitis, 
and cardiac arrhythmias. Adverse events were defined and graded 
in accordance with the Division of AIDS Table for grading the 
severity of adult and pediatric adverse events11.
Sample size
The original sample size was determined on the basis of 
the primary outcome endpoint of efficacy. To calculate sample 
size, an ideal setting with unlimited number of patients was 
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Assessed for eligibility (n=135) 
Excluded (n=34) 
♦Not meeting inclusion criteria (n=14) 
♦Declined to participate (n=14) 
♦Residence too far away to ensure 
follow-up (n=6) 
Analyzed per protocol (n=48) 
Analyzed by intention to treat (n=51) 
Lost to follow-up (n=0) 
Relapse until D180 (n=0) 
Antimonial group–allocated to therapy with 
N-methylglucamine antimoniate (n=51) 
♦Received allocated intervention (n=48) 
♦Removed because of severe adverse 
events (n=3) 
Lost to follow-up (n= 0) 
Relapse until D180 (n=1) 
ABD group–allocated to therapy with 
amphotericin B deoxycholate (n=50) 
♦Received allocated intervention (n=48) 
♦Removed because of severe adverse 
events (n=2) 
Analyzed per protocol (n=48) 









FIGURE 1 - Amphotericin B deoxycholate versus N-methylglucamine antimoniate: CONSORT (Consolidated Standards of Reporting Trials) flow diagram.
simulated and the formula suggested by Pocock was applied12. 
The required sample size was 283 subjects in each group. As a 
pilot trial, this study was projected with 50 individuals in each 
arm to evaluate the protocol.
Randomization
Randomization procedure was performed in blocks of 
20, using Graphpad Quickcalcs free software (GraphPad 
Software Inc., San Diego, CA). This procedure was under 
the responsibility of an independent researcher from Tropical 
Medicine Center at Universidade de Brasília, who was not 
directly involved in any other operational aspect of the study. 
The names of compared drugs were typed on a sheet and placed 
in dark envelopes, which were sealed, stamped, and signed by 
those responsible for the randomization. The envelopes were 
opened immediately after the consent of the participants.
Blinding
This was an open-label trial. It was possible to mask 
the assessment of the hematological and biochemical tests. 
Laboratory technicians did not have access to patient’s data, they 
had no direct contact with the investigators, and no information 
regarding the drug administered to the patients. No blinding was 
applied for the evaluation of clinical outcomes.
Statistical analysis
Statistical Package for Social Science (SPSS) version 18.0 
(SPSS Inc., Chicago, IL) was used for systematization of clinical 
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and laboratory information. Data were analyzed with the same 
software. The two randomized groups were first compared with 
respect to baseline clinical and laboratory data. Proportions were 
compared through Yates’ chi-square test. T-test for independent 
groups was used for continuous variables. Mann-Whitney U 
test was used for variables showing abnormal distributions. 
Differences were considered statistically significant at p-value 
< 0.05. The analysis of primary outcome was planned on 
an intention-to-treat basis (ITT) considering all subjects as 
originally assigned to the two arms. Patients who needed therapy 
change due to adverse effects and those lost during treatment or 
follow-up were considered as treatment failures. No subgroup 
analysis was initially planned.
RESULTS
The study was conducted between January 2006 and January 
2009. A total of 135 children who met the suspect VL case 
definition as described above were screened and subsequently 
diagnosed with VL through laboratorial tests. Thirty-four 
children were initially excluded because of parents or legal 
guardians decline to participate (n=14), living far away from the 
study center (n=6), or not complying with the inclusion criteria 
(n=14). Of the recruited patients, 51 were randomly assigned 
to MA arm and 50 to ABD arm. Follow-up was completed by 
all participants in both arms (Figure 1).
Baseline data
The main baseline characteristics of the included children 
(101 patients) are reported in Table 1. 
The median age was 38 months [range 6-143 months; 56 
(55%) male] while children aged <5 and <2 years constituted 
64.4% and 33.7% of the sample, respectively. Most patients 
were from the State of Tocantins, but 2 patients lived in the 
State of Pará.
The baseline characteristics of both arms were similar, with 
the exception of liver size measured below the right costal 
margin (median 4cm for antimonial group vs 5cm for ABD 
group; U=989, p=0.04) and spleen size measured below the 
left costal margin (median 6cm for antimonial group vs. 8cm 
for ABD group; U=878, p=0.02).
All patients included in the study had clinical features 
of VL. The main clinical signs on admission were fever in 
100 (99%) patients, mucocutaneous pallor in 98 (97%), 
tachycardia in 76 (75.2%), hepatomegaly in 98 (97%), and 
splenomegaly in 101 (100%). Other signs and symptoms 
were vomiting in 48 (47.5%) patients, lethargy in 9 (8.9%), 
and localized edema in 3 (2.9%). Anemia (hemoglobin < 11g/
dL), leucopenia (white blood cells - WBC < 5,000 cells/mm3), 
or thrombocytopenia (platelets < 150,000/mm3) were present in 
89 (88.6%) patients. No patient had renal failure or hematuria 
at admission. Jaundice was observed in 4 children, but the 
aminotransferases and bilirubin levels 50% above the upper limit 
of normal occurred in 57% of patients. Twenty-two patients had 
serum albumin levels below 2g/dL.
The VL diagnosis was confirmed in all participants. 
Bone marrow direct examination was positive for 97 (96%) 
individuals. Four patients were diagnosed using PCR (one with 
positive indirect immunofluorescence test - IFI - and rapid test, 
and another with positive IFI).
Efficacy
Based on ITT analysis, cure was observed in 94.1% (48/51) 
of patients in antimonial group and in 94% (47/50) of patients in 
ABD group (p=0.62). Therefore, the observed difference in cure 
rate was 0.1% [95% confidence interval (CI) = -8.99-9.39] in the 
ITT analysis. The between-group difference in definitive cure rates 
in the ITT analysis was 0.1%, with 95% CI = -10.67-11.04. Most 
failures considered in the ITT analysis (5/6) were children who 
had to discontinue the therapy owing to serious adverse reactions 
and the remaining failure was due to relapse that occurred in one 
patient from ABD group in the sixth month of follow-up. 
According to per protocol analysis, all (except one child from 
ABD group) patients who completed treatment were cured. In 
this analysis, 48 children treated with MA and 48 treated with 
ABD were included. The observed difference in cure rate was 
2.1% with 95% CI= -5.52-10.9 (Table 2). 
Secondary outcomes
The time elapsed until fever resolution was significantly 
shorter in antimonial group (22 children had complete remission 
in 48 hours), whereas eight patients in ABD group showed the 
same outcome (χ2 = 8.91, p < 0.01). Differences in reduction of 
spleen size were found between the groups: median spleen size 
at hospital discharge was 3 cm (50% reduction from admission 
spleen size) in antimonial group and 3.75cm (53% reduction 
from admission size) in ABD group (U=796.5, p < 0.01). The 
time elapsed until normalization of hemoglobin was evaluated at 
D60 and D90, and no difference was found between groups. In 
D60, 17 (34%) patients from antimonial group still had anemia 
(hemoglobin < 11g/dL), while 22 (43%) from ABD group 
remained with anemia. In D90, anemia was found in 8 (16%) 
children from antimonial group and in 10 (20%) patients from 
the ABD group (χ2 = 0.09, p = 0.76). No patient died during the 
study period. Time elapsed for normalization of other laboratory 
tests was evaluated at D90, and no differences were found 
between groups. Most patients (80%) showed normalization of 
hematological and biochemical indices in D90. The remainder 
persisted just with anemia.
Adverse events
All patients (in both groups) experienced at least one adverse 
event. Three serious adverse events occurred in antimonial 
group and 2 in ABD group, but no significant difference was 
found between the groups (χ2 = 0.19, p = 0.98). The main serious 
adverse events noted during hospitalization were abnormal liver 
enzymes, anemia, and hypomagnesemia (Table 3). 
Patients in antimonial group had a higher frequency of 
serious adverse events requiring the withdrawal of research 
subjects. Most often adverse events observed in antimonial 
group were liver enzyme abnormalities (found in 18.8% of 
patients in D7, in 21.9% in D14, and in 17.6 % in D20), myalgia 
(n=32), anemia (severe in 37) and hypomagnesemia (severe 
in 24). Hypokalemia and hyponatremia events were considered 
Borges MM et al. - Pediatric kala-azar treatment: an open-label pilot trial
  71
Antimonial group
N-methylglucamine antimoniate (N= 51)
ABD group
Amphotericin B deoxycholate (N= 50)
Outcomes
Early failure because of drug toxicity 3 2
Completed treatment 48 48
Relapse* 0 1
Lost to follow-up 0 0
Definitive cure at 6 months
Intention-to-treat approach
number of cured patients 













Amphotericin B deoxycholate versus N-methylglucamine antimoniate for pediatric visceral leishmaniasis treatment: efficacy data.
* Relapse was diagnosed in one boy at the final of follow-up (D180).
ABD: amphotericin B deoxycholate; 95% CI: 95%confidence interval; D180: day 180.
Variable Antimonial groupN-methylglucamine antimoniate (N= 51)
ABD group
Amphotericin B deoxycholate (N= 50) 
Age (months) 52.65 52.37
Male (%) 49 62.0
Weight (kg) 14.1 13.3
Fever (%) 94 88.0
Pallor (%) 96 100.0
Hepatomegaly (%) 96 100.0
Splenomegaly (%) 96 100.0
Associated bacterial infection (%)* 65 76.0
Spleen size: median of cm below the left costal margin 6 8
Liver size: median of cm below the right costal margin 4 5
Hemoglobin (g/dl) 7.81 7.67
White-cell count (per mm3) 3,754 3.139
Platelet count (per mm3) 142.780 117.509
Total bilirubin (mg/dl) 0.58 0.64
AST (IU/ml) 101.18 88.57
ALT (IU/ml) 69.4 69.31
Albumin (g/dl) 2.3 2.2
Globulin (g/dl) 3.7 3,8
Creatinine (mg/dl) ** 0.495 0.493
Blood urea nitrogen (mg/dl) *** 21.44 17.22
TABLE 1
Baseline clinical and laboratory data of patients with visceral leishmaniasis.
* Bacterial infection was diagnosed on the basis of clinical suspect and/or positive cultures. ** To convert the values for creatinine to micromoles per liter, multiply 
by 88.4. *** To convert the values for blood urea nitrogen to micromoles per liter, multiply by 0.357.
ABD: amphotericin B deoxycholate; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
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mild, but moderate hypocalcemia and severe hypocalcemia 
were observed in 8 and 2 children, respectively. Moderate 
hypomagnesaemia was observed in 15 patients, and 24 had 
very low magnesium levels. Gastrointestinal disorders such 
as nausea, vomiting, and abdominal pain were also reported. 
Cardiac arrhythmia was observed in 4 children from antimonial 
group, with no reported cases in ABD group (p = 0.13). 
Electrocardiographic changes associated with antimonial use 
were sinus arrhythmia associated with septal repolarization 
changes observed in 3 children and right branch conduction 
disturbance in one male child. 
In the ABD group, increased frequency of anemia and 
hypomagnesaemia was found. Severe anemia was observed in 
37 (74%) patients and 7 patients had moderate (n=5) or severe 
thrombocytopenia (n=2). Adverse events related to electrolytes 
were moderate hyponatremia, hypokalemia, and hypocalcemia, 
but magnesium levels dropped in 39 (78%) patients, with 
severe drop (below the minimum acceptable level) in 20 (40%) 
children. Ten children in ABD group reported shivers, and 
2 maintained this complaint in D7. None of the patients had 
abnormal amylase, creatin kinase, creatinine, or urea levels. 
Other reported adverse events were changes in liver enzymes, 
gastrointestinal disorders (nausea, vomiting, abdominal pain, 
and constipation), myalgia, and arthralgia. Analysis showed that 
frequency of adverse events was similar between groups, except 
for abnormal aminotransferases levels (prevalent on antimonial 
group) and shivers (prevalent in ABD group). 
DISCUSSION
Approximately two-thirds of the drugs used in pediatric 
clinical practice do not have enough evidence about dosages, 
safety, and efficacy for each phase of development13. Children 
compose a substantial proportion of the population of patients 
with VL, particularly in New World VL. They seemed to 
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Event
Antimonial group
N-methylglucamine antimoniate N= 51 (%)
ABD group
Amphotericin B deoxycholate N= 50 (%) P-value*
moderate severe moderate severe
Abdominal pain (N/%) 2 (3.9) - 5 (10.0) - 0.42
Constipation (N/%) 1 (1.9) - - - 0.99
Diarrhea (N/%) 2 (3.9) - 2 (4.0) - 0.62
Myalgia/arthralgia (N/%) 37 (72.5) - 35 (70.0) - 0.78
Nausea/vomiting (N/%) 29 (56.9) - 35 (70.0) - 0.24
Phlebitis (N/%) 1 (1.9) - 3 (6.0) - 0.61
Shivers (N/%) 1 (1.9) - 10 (20.0) - 0.01
Worsening anemia (N/%) 13 (21.5) 37 (72.5) 10 (20.0) 37 (74.0) 0.59
Worsening 
thrombocytopenia (N/%)
24 (47.1) 2 (3.9) 23 (46.0) 2 (4.0) 0.92
Abnormal alkaline 
phosphatase (N/%) 
2 (3.9) - 3 (6.0) - 0.98
Abnormal ALT (N/%) 14 (27.5) 16 (31.3) 8 (16.0) 10 (20.0) 0.04
Abnormal AST (N/%) 20 (39.2) 8 (15.6) 10 (20.0) 6 (12.0) 0.03
Abnormal γ-glutamyl 
transpeptidase (N/%)
8 (15.6) 3 (5.8) 2 (4.0) 2 (4.0) 0.09
Abnormal total bilirubin 
(N/%)
1 (1.9) - 1 (2.0) - 0.48
Hypocalcemia (N/%) 8 (15.6) 2 (3.9) 6 (12.0) 2 (4.0) 0.79
Hypokalemia (N/%) 11 (21.6) 1 (1.9) 11 (22.0) - 0.85
Hypomagnesemia (N/%) 15 (24.0) 24 (47.0) 19 (38.0) 20 (40.0) 0.85
Hyponatremia (N/%) 25 (49.0) - 25 (50.0) - 0.92
TABLE 3
Safety data of Amphotericin B deoxycholate versus N-methylglucamine antimoniate for pediatric visceral leishmaniasis. 
* P-value calculated by counting the total of moderate and severe adverse events described for each arm. 
ABD: amphotericin B deoxycholate; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
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have lower response rates to treatment, as well as recruitment 
difficulties in areas of high incidence of the disease and lack 
of diagnostic resources. To our knowledge, this is the first trial 
with focus on treatment with antimonial vs. ABD for pediatric 
visceral leishmaniasis in the New World. Both treatment groups 
were comparable at baseline by most of the recorded clinical and 
laboratory variables. Differences observed in the spleen size (2 cm 
larger in ABD group) and liver size (1cm larger in ABD group) had 
no clinical significance. In addition, both arms showed comparable 
efficacy, with no significant difference between groups. 
The antimonial efficacy described in this study was high as 
per protocol analysis, but serious toxicity could have a negative 
impact on the efficacy, as indicated by the ITT analysis. It is 
described that sodium stibogluconate and N-methylglucamine 
antimoniate have comparable efficacy and toxicity14. Most of 
the studies that evaluate efficacy of antimonials for VL therapy 
are retrospective and performed in the Indian subcontinent. 
Average effectiveness of intramuscular antimonials assessed 
after six months without relapse was estimated in 92% of cases 
(range, 36-96%), based on previous studies15. Our study shows 
an efficacy comparable with that of previous studies. A Greek 
study described a 90.3% efficacy of using MA for 30 days in 
children16. However, since 1990s, increasing resistance to 
antimonials in Indian VL has been observed primarily in Bihar 
and adjacent territories. Randomized controlled trials with 
Indian patients with VL from 1992 to 2000 showed an efficacy 
of 36 to 69%, with an average of 50%15-18. As antimonials, 
ABD has been poorly evaluated in children with VL. Indian 
studies showed an efficacy ranging between 91.3 and 97% 
when compared to miltefosine19,20. Average effectiveness of 
ABD assessed after 6 months of follow-up was estimated at 
97% (range 96-99%), based on six studies performed in the 
Indian subcontinent15. Our study showed a lower efficacy 
rate than that of previous studies. Lipidic formulations are 
considered comparable in efficacy, but with less toxicity21. 
Patients treated with antimonials had more effective response 
with the disappearance of fever during the first 48 hours, 
the opposite was observed in patients treated with ABD, in 
whom fever lasted longer than 72 hours. This observation is 
different from findings in the majority of previous studies 
comparing antimonials vs. amphotericin B22. Two studies 
performed in children with Mediterranean VL also showed 
earliest resolution of fever with amphotericin B16,23. Since this 
study had a limited population, this data should be reviewed 
in future studies with a larger sample group.
The toxicity observed in the present study was typical for 
used drugs and no unexpected adverse event was observed. Both 
drugs caused severe adverse events that precluded treatment 
continuation; this should be considered when planning the 
administration of antimonials to outpatients. Participants 
of the present study were treated after excluding signs and 
laboratory abnormalities commonly observed in severe cases. 
Serious adverse events observed in this trial can affect children 
without severe disease and can be fatal if managed in outpatient 
settings. Finally, although both treatments seemed to be similarly 
effective, ABD had the advantage of a shorter course.
Study limitations
Blinding was not possible owing to differences in 
formulations, time for treatment, and operational causes. This 
could have affected the assessment of efficacy, but we consider 
it unlikely, as the primary outcome was based on a long 
follow-up. The laboratory staff was blinded to the administered 
treatments. However, clinical side effects reporting may have 
been influenced both by the investigator’s and the patients’ 
parents or guardians knowledge of being research subjects. 
Results should be interpreted with caution because this study 
was a pilot trial, with a limited number of participants. Efficacy 
data reported cannot be extrapolated to children with human 
immunodeficiency virus/acquired immunodeficiency syndrome 
(HIV/AIDS) or those with severe disease. On conclusion of 
this study, it was designed an open, controlled, randomized and 
multicenter clinical trial to evaluate the efficacy of four regimens 
for VL treatment in Brazil, including the liposomal formulation 
of amphotericin B (www.clinicaltrials.gov NCT01310738).
Conclusions and future directions
Both evaluated regimes (N-metilglucamine antimoniate 
and amphotericin B deoxycholate) used as first-line therapy in 
Brazil at the time the trial was conducted were effective with 
reasonable safety profile for most of the patients. However, 
serious adverse events occurrence suggest that high experienced 
clinical physicians are necessary for adequate management to 
avoid lethal outcomes. Toxicity profile was different between 
groups. Antimonial group had higher frequency of abnormal 
alanine transaminase (ALT) and aspartate transaminase (AST), 
while amphotericin group had higher frequency of shivers.
Results observed in both groups regarding cure rates suggest 
an equivalent effectiveness of tested regimens, with estimated 
difference of 2.1% and maximum inaccuracy rate of 10%. The 
appearance of relapses in a period over 6 months suggests the need 
to extend the monitoring period for 12 months after completion 
of therapy. The shorter course of treatment with amphotericin B 
should be considered an advantage over the antimonials treatment 
schedule of 20 days, mainly because the inpatient regimen is 
also recommended for antimonials. A pharmacokinetic study 
of antimonials in children would be particularly important to 
determine whether the relevant clinical effects could differ in 
accordance with age and the standard dose used.
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